InvestSMART

Syntara Limited (ASX: SNT) - Announcements

- Current share price for SNT : $0.020

ASX company news and announcements for Syntara Limited (SNT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Syntara Limited (SNT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Syntara Limited (SNT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Syntara Limited (SNT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$39 Notification of cessation of securities - SNT 10 Mar 2026 4:33PM $0.030 $0.020 fallen by 33.33%
$39 Application for quotation of securities - SNT 27 Feb 2026 1:22PM $0.031 $0.020 fallen by 35.48%
$39 Half Year Report and Appendix 4D 26 Feb 2026 8:34AM $0.032 $0.020 fallen by 37.50%
$39 Application for quotation of securities - SNT 23 Feb 2026 1:44PM $0.034 $0.020 fallen by 40.30%
$39 Notification regarding unquoted securities - SNT 18 Feb 2026 10:57AM $0.034 $0.020 fallen by 41.18%
$39 Investor Presentation Euroz Hartleys Healthcare Forum 5 Feb 2026 8:58AM $0.034 $0.020 fallen by 41.18%
$39 2026 Outlook Webinar Presentation 3 Feb 2026 10:37AM $0.031 $0.020 fallen by 35.48%
$39 Application for quotation of securities - SNT 2 Feb 2026 10:32AM $0.031 $0.020 fallen by 35.48%
$39 2026 Outlook Webinar and Q&A 29 Jan 2026 10:20AM $0.034 $0.020 fallen by 41.18%
$39 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jan 2026 10:02AM $0.035 $0.020 fallen by 42.86%
$39 Amsulostat and Garvan in MRFF funded pancreatic trial 21 Jan 2026 10:00AM $0.033 $0.020 fallen by 39.39%
$39 Notification regarding unquoted securities - SNT 8 Jan 2026 2:11PM $0.033 $0.020 fallen by 39.39%
$39 Company Secretary Appointment/Resignation 8 Jan 2026 2:03PM $0.033 $0.020 fallen by 39.39%
$39 SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited 8 Jan 2026 9:30AM $0.033 $0.020 fallen by 39.39%
$39 Letter to Shareholders 23 Dec 2025 9:06AM $0.029 $0.020 fallen by 31.03%
$39 Amsulostat data to be presented at ASH 5 Dec 2025 8:23AM $0.032 $0.020 fallen by 37.50%
$39 SNT 9465 Webinar 26 Nov 2025 11:07AM $0.031 $0.020 fallen by 35.48%
$39 Change of Director's Interest Notice - GP 26 Nov 2025 9:20AM $0.030 $0.020 fallen by 33.33%
$39 Change of Director's Interest Notice - KM 26 Nov 2025 9:20AM $0.030 $0.020 fallen by 33.33%
$39 Notification regarding unquoted securities - SNT 26 Nov 2025 9:19AM $0.030 $0.020 fallen by 33.33%
$39 Notification regarding unquoted securities - SNT 26 Nov 2025 9:17AM $0.030 $0.020 fallen by 33.33%
$39 Notification regarding unquoted securities - SNT 26 Nov 2025 9:17AM $0.030 $0.020 fallen by 33.33%
$39 Skin scarring program to progress on positive Phase1a result 26 Nov 2025 9:06AM $0.030 $0.020 fallen by 33.33%
$39 Topical Pan-Lox Inhibition for Skin Scarring KOL webinar 24 Nov 2025 4:10PM $0.030 $0.020 fallen by 33.33%
$39 Initiation of amsulostat Phase 2 MESSAGE trial in MDS 21 Nov 2025 9:36AM $0.030 $0.020 fallen by 33.33%

51 - 75 of 280 results

Page 3 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.